IR – Abliva

12 January, 2021

Abliva Announces Termination of License Agreement with Fortify Therapeutics

Abliva AB (Nasdaq Stockholm: ABLI) today announced that the license agreement with Fortify Therapeutics, a wholly-owned subsidiary of BridgeBio, regarding a development of a local treatment for Leber’ ...

4 January, 2021

Ablivas KL1333 heading for phase II/III in 2021

Abliva can look back on an eventful year, which was marked by the strategy shift towards treatments for mitochondrial diseases made last year. Several important milestones have been passed - including ...

20 November, 2020

Regulatory

Abliva AB Interim Report January – September 2020

KL1333 is on its way to pivotal clinical study - Pivotal study planned for the second half of 2021

17 November, 2020

Abliva receives positive regulatory feedback from UK MHRA on KL1333 Phase II/III study plan

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announced it has received ...

10 November, 2020

Abliva initiates a drug-drug interaction study and paves the way for a KL1333 pivotal study in 2021

8 October, 2020

Regulatory

Magnus Persson leaves the Board of Directors of Abliva AB to focus on role as founding partner at Eir Ventures

Abliva AB (Nasdaq Stockholm: ABLI) today announces that Magnus Persson is leaving the company's Board of Directors at his own request, to focus on his role as founding Partner at Eir Ventures, a recen ...

7 October, 2020

Abliva doses the first patient in its KL1333 Phase Ia/b clinical study

Abliva AB (Nasdaq Stockholm: ABLI) today announced that the first primary mitochondrial disease patient in the company’s ongoing KL1333 Phase Ia/b study has been dosed. In this third part of the study ...

16 September, 2020

Abliva’s Mitochondria Day – today at 2 p.m. – 4 p.m. CEST

Abliva AB (Nasdaq Stockholm: ABLI) welcomes, on the occasion of The World Mitochondrial Disease Week, to its virtual Mitochondria Day 2020, today on 16 September at 2 p.m. – 4 p.m. CEST. The purpose o ...

9 September, 2020

Regulatory

Abliva intends to start a pivotal KL1333 study second half 2021

Abliva AB (Nasdaq Stockholm: ABLI) today announced that the company’s Board of Directors has decided to accelerate the KL1333 clinical program, with the intention to start a pivotal Phase II/III clini ...

26 August, 2020

Abliva arranges Mitochondria Day on 16 September 2020 – preliminary program

Abliva AB (Nasdaq Stockholm: ABLI) welcomes, on the occasion of The World Mitochondrial Disease Week, to its virtual Mitochondria Day 2020, on 16 September at 2 p.m. – 4 p.m. CEST. The purpose of the ...

21 August, 2020

Regulatory

Abliva AB Interim Report January – June 2020

NeuroVive Pharmaceutical AB changes its name to Abliva AB - Two share issues bring a total of MSEK 87 to Abliva - Hadean Ventures new strategic owner

12 August, 2020